Skip to content
DataLookout
Menu

NCT07723976

A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Recruitment opened
    • Eligibility criteria expanded, about 13 words
    • Trial sites expanded: 0 → 43 locations
  2. Minor Study title shortened, about 6 wordsv2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change in Countable Motor Seizure Frequency Per 28 Days
Timeframe: Baseline up to 6 weeks of double-blind treatment period

Secondary (11)

Change in Total Seizure Frequency Per 28 Days
Proportion of Participants Who Achieve ≥ 50% Reduction From Baseline in Countable Motor Seizure Frequency
Caregiver Global Impression of Change (CaGI-C) Score
Change from Baseline in Caregiver Global Impression of Severity (CaGI-S) Score
Change From Baseline in Number of Countable Motor Seizure-free Days per 28 Days
Show 6 moreShow less
Clinical Global Impression of Change (CGI-C) Score
Change from Baseline in Clinical Global Impression of Severity (CGI-S) Score
Number of Participants Reporting Treatment-emergent Adverse Events
Mean Plasma Concentration of CBD
Mean Plasma Concentration of Metabolite 7-OH-CBD
Mean Plasma Concentration of Metabolite 7-COOH-CBD

Arms and interventions

CBD-OSExperimental

Participants with DEE will be randomized to CBD-OS up to 10 mg/kg twice daily for a 6-week treatment period.

PlaceboPlacebo comparator

Participants with DEE will be randomized to matching placebo for a 6-week treatment period.

Open-Label Extension: CBD-OSExperimental

Participants with DEE who completed the double-blind phase of the study and enter the optional OLE will begin a 22-week open-label treatment period with CBD-OS up to 10 mg/kg twice daily following a 2-week Blinded Transition Period.

Drugs: CBD-OS, Placebo

Sites

43 sites in 5 countries

United States 18, Italy 9, Australia 7, Spain 6, Hungary 3